JP7850460B2 - ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用 - Google Patents

ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用

Info

Publication number
JP7850460B2
JP7850460B2 JP2023547753A JP2023547753A JP7850460B2 JP 7850460 B2 JP7850460 B2 JP 7850460B2 JP 2023547753 A JP2023547753 A JP 2023547753A JP 2023547753 A JP2023547753 A JP 2023547753A JP 7850460 B2 JP7850460 B2 JP 7850460B2
Authority
JP
Japan
Prior art keywords
cancer
compounds
cells
compound
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545588A5 (https=
JP2023545588A (ja
Inventor
ウィンター，ゲオルク
マヨール・ルイス，クリスティナ
クビチェク，シュテファン
ドナルド，アラステア・ダーヴィト・グラハム
ツェンケヴィキウト，グラシルダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proxygen GmbH
Original Assignee
Proxygen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proxygen GmbH filed Critical Proxygen GmbH
Publication of JP2023545588A publication Critical patent/JP2023545588A/ja
Publication of JP2023545588A5 publication Critical patent/JP2023545588A5/ja
Application granted granted Critical
Publication of JP7850460B2 publication Critical patent/JP7850460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023547753A 2020-10-16 2021-10-15 ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用 Active JP7850460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20202417.0 2020-10-16
EP20202417 2020-10-16
PCT/EP2021/078696 WO2022079290A2 (en) 2020-10-16 2021-10-15 Cullin ring ubiquitin ligase compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2023545588A JP2023545588A (ja) 2023-10-30
JP2023545588A5 JP2023545588A5 (https=) 2024-11-08
JP7850460B2 true JP7850460B2 (ja) 2026-04-23

Family

ID=72964476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547753A Active JP7850460B2 (ja) 2020-10-16 2021-10-15 ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用

Country Status (7)

Country Link
US (1) US20240132485A1 (https=)
EP (1) EP4229037A2 (https=)
JP (1) JP7850460B2 (https=)
CN (1) CN116568671A (https=)
AU (1) AU2021359129A1 (https=)
CA (1) CA3194868A1 (https=)
WO (1) WO2022079290A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN116003424B (zh) * 2022-11-30 2024-03-19 中国药科大学 Shp2与mek1双靶点抑制剂及其制备方法与应用
JP2026501188A (ja) * 2022-12-16 2026-01-14 杭州阿諾生物医薬科技有限公司 サイクリンｋ分解剤及びその使用
AU2024327686A1 (en) * 2023-08-18 2026-03-12 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025104236A1 (en) * 2023-11-15 2025-05-22 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
CN119707806B (zh) * 2024-12-24 2025-12-12 河南师范大学 可见光催化不对称反应制备手性2-氮杂芳烃酰胺的方法

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522842A (ja) 1997-11-12 2001-11-20 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼのアミノチアゾール系阻害剤
JP2002528537A (ja) 1998-10-30 2002-09-03 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー ２−アミノ−チアゾール誘導体類、それらの製造方法および抗癌剤としてのそれらの使用
JP2002338556A (ja) 2001-05-11 2002-11-27 Pfizer Prod Inc チアゾール誘導体
JP2003507329A (ja) 1999-08-12 2003-02-25 フアルマシア・イタリア・エツセ・ピー・アー ３（５）−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用
JP2003516981A (ja) 1999-12-15 2003-05-20 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼのアミノチアゾール阻害剤
JP2004507526A (ja) 2000-08-31 2004-03-11 ファイザー・プロダクツ・インク ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
JP2008255123A (ja) 2000-07-31 2008-10-23 Pfizer Prod Inc イミダゾール誘導体
JP2010507575A (ja) 2006-10-21 2010-03-11 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
WO2016104434A1 (ja) 2014-12-24 2016-06-30 武田薬品工業株式会社 複素環化合物
JP2016539174A (ja) 2013-12-02 2016-12-15 シエナ・バイオテック・エス・ピー・エー Ｓ１ｐ３アンタゴニスト
JP2017505808A (ja) 2014-01-06 2017-02-23 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
JP2017516830A (ja) 2014-06-03 2017-06-22 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
JP2018502544A (ja) 2014-12-19 2018-01-25 ノルディック セミコンダクタ アーエスアーＮｏｒｄｉｃ Ｓｅｍｉｃｏｎｄｕｃｔｏｒ ＡＳＡ 集積回路
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
JP2020523379A (ja) 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のためのベンゾフランアミドおよびそれらの複素芳香族アナログ

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU756693B2 (en) 1997-09-29 2003-01-23 Novartis Ag Stabilized bioactive preparations and methods of use
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
CA2392576A1 (en) * 1999-11-24 2001-05-31 Lingyan Wang .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
EP2121619A2 (en) * 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
AU2009276548A1 (en) * 2008-07-30 2010-02-04 Oncotherapy Science, Inc. Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same
WO2012014699A1 (ja) * 2010-07-28 2012-02-02 湧永製薬株式会社 神経疾患治療薬
GB2513403A (en) * 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
CN104447733B (zh) * 2015-01-05 2016-08-17 中国药科大学 1-苄基-2-吡咯啉酮-4-酰胺类化合物及其制备方法与应用
GB201501870D0 (en) * 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
WO2018129381A1 (en) * 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11497752B2 (en) * 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
CN113645971B (zh) * 2019-01-29 2024-10-18 福宏治疗公司 化合物及其用途
IL284589B2 (en) * 2019-01-31 2025-10-01 Pfizer 3–Carbonylamino–5–cyclopentyl–h1–pyrazole compounds with cdk2 inhibitory activity

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522842A (ja) 1997-11-12 2001-11-20 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼのアミノチアゾール系阻害剤
JP2002528537A (ja) 1998-10-30 2002-09-03 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー ２−アミノ−チアゾール誘導体類、それらの製造方法および抗癌剤としてのそれらの使用
JP2003507329A (ja) 1999-08-12 2003-02-25 フアルマシア・イタリア・エツセ・ピー・アー ３（５）−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用
JP2003516981A (ja) 1999-12-15 2003-05-20 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼのアミノチアゾール阻害剤
JP2008255123A (ja) 2000-07-31 2008-10-23 Pfizer Prod Inc イミダゾール誘導体
JP2004507526A (ja) 2000-08-31 2004-03-11 ファイザー・プロダクツ・インク ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
JP2002338556A (ja) 2001-05-11 2002-11-27 Pfizer Prod Inc チアゾール誘導体
JP2010507575A (ja) 2006-10-21 2010-03-11 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
JP2016539174A (ja) 2013-12-02 2016-12-15 シエナ・バイオテック・エス・ピー・エー Ｓ１ｐ３アンタゴニスト
JP2017505808A (ja) 2014-01-06 2017-02-23 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
JP2017516830A (ja) 2014-06-03 2017-06-22 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
JP2018502544A (ja) 2014-12-19 2018-01-25 ノルディック セミコンダクタ アーエスアーＮｏｒｄｉｃ Ｓｅｍｉｃｏｎｄｕｃｔｏｒ ＡＳＡ 集積回路
WO2016104434A1 (ja) 2014-12-24 2016-06-30 武田薬品工業株式会社 複素環化合物
JP2020523379A (ja) 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のためのベンゾフランアミドおよびそれらの複素芳香族アナログ
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur. J. Pharm. ，2013年，720，383-390

Also Published As

Publication number Publication date
US20240132485A1 (en) 2024-04-25
JP2023545588A (ja) 2023-10-30
CN116568671A (zh) 2023-08-08
AU2021359129A1 (en) 2023-06-01
WO2022079290A2 (en) 2022-04-21
WO2022079290A3 (en) 2022-06-16
AU2021359129A9 (en) 2024-06-20
CA3194868A1 (en) 2022-04-21
EP4229037A2 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
JP7850460B2 (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
Smith et al. Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5• MTA complex for the treatment of MTAP-deleted cancers
US10702518B2 (en) TAF1 inhibitors for the therapy of cancer
AU2020366135B2 (en) Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
KR101928225B1 (ko) Ｎ-(시아노메틸)-4-(2-(4-모르폴리노페닐아미노)피리미딘-4-일)벤즈아미드 히드로클로라이드 염
JP2020514254A (ja) がん治療のための組成物および方法
JP6684831B2 (ja) 化合物
CN107531683B (zh) Usp7抑制剂化合物及使用方法
US11014902B2 (en) MYC G-quadruplex stabilizing small molecules and their use
RU2641693C2 (ru) Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
US20240190838A1 (en) Lzk-targeting degraders and methods of use
Oh et al. Discovery of 2, 6-Naphthyridine analogues as selective FGFR4 inhibitors for hepatocellular carcinoma
WO2021074418A1 (en) Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
WO2023203172A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2020152462A1 (en) Pyrrolobenzodiazepine derivatives as inhibitors of nf-kappa b for the treatment of proliferative diseases
Mohammed et al. Discovery of 2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno [3, 2-D] pyrimidines as orally bioavailable phosphoinositide-3-kinase inhibitors with in vitro and in vivo antitumor efficacy in triple-negative breast cancer
EP4393908A1 (en) Bis-pyrazolyl-methane compounds affecting kras
WO2025017207A1 (en) Inhibitors of smndc1 and their therapeutic use
WO2025104236A1 (en) Pyrazole compounds as cullin ring ubiquitin ligase compounds
Zhao Small Molecules for Active Targeting and Development of PROTACs
WO2024249959A1 (en) Compositions reducing the expression or activity of c1 galt1 for treating ewing sarcoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241009

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260406

R150 Certificate of patent or registration of utility model

Ref document number: 7850460

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150